Tumor Markers and Serum Electrophoresis: Their Role in Diagnosing Multiple Myeloma

Multiple myeloma is a malignant disease of plasma cells that can cause renal failure, normocytic anemia, hypercalcemia, and raised ESR. To diagnose multiple myeloma, serum electrophoresis, serum-free light-chain assay, and assessment of urinary Bence Jones protein are recommended. Serum electrophoresis confirms the presence of a paraprotein, which may be due to myeloma or MGUS. Further tests, such as bone marrow biopsy, magnetic resonance imaging, and immunofixation of serum and urine, are usually carried out in secondary care to confirm the diagnosis.

Carcinoembryonic antigen (CEA), CA 19-9, serum lactate dehydrogenase (LDH), and CA125 are tumor markers used to monitor disease progression in various cancers. However, there is no role for these markers in diagnosing multiple myeloma. CEA is mainly used to monitor the progress of treatment for colonic cancer, while CA 19-9 is used to monitor disease progression in pancreatic cancer. LDH is raised in lymphoma and certain types of testicular cancer, and CA125 is used in the diagnosis of ovarian cancer. Therefore, these markers are not useful in diagnosing multiple myeloma.

Investigations for Thrombotic Thrombocytopenic Purpura in a Pregnant Patient with Fever and Confusion

Thrombotic thrombocytopenic purpura (TTP) should be considered in a pregnant patient presenting with fever, acute kidney injury, cerebral dysfunction, thrombocytopenia, and microangiopathic hemolytic anemia. To confirm the diagnosis, a blood film is needed to show the presence of schistocytes from the destruction of red blood cells. An abdominal ultrasound may be considered, but it will not aid in identifying the underlying diagnosis. Although a blood culture is appropriate, it would not confirm the diagnosis. A CT head or lumbar puncture may be useful in excluding visible organic pathology, but they do not play a role in the diagnosis of TTP.

Lynch syndrome is a genetic condition that increases the risk of developing colorectal cancer by over 80%. It also raises the risk of other cancers such as endometrial, stomach, breast, ovarian, small bowel, pancreatic, prostate, urinary tract, kidney, and liver cancer. Genetic testing is recommended for anyone diagnosed with colorectal cancer, regardless of age.

Breast cancer (BRCA) mutations are inherited in an autosomal dominant pattern and significantly increase the risk of developing breast, ovarian, prostate, and pancreatic cancer. These cancers tend to occur at a younger age than in the general population. While there is a possible link to colorectal pathology, other genetic syndromes should be considered first when looking for a genetic cause of cancer.

Cowden syndrome is a rare genetic condition characterized by benign growths called hamartomas on various parts of the body. It increases the risk of developing breast, thyroid, or endometrial cancer but has no association with colorectal cancer.

Familial adenomatous polyposis is an autosomal dominant condition that causes widespread colorectal adenomas, with polyps usually developing in late childhood. This greatly increases the risk of colorectal cancer, and prophylactic colectomy is often performed. Screening is recommended for those with an affected first-degree relative or multiple polyps detected on colonoscopy.

Von Hippel-Landau (VHL) syndrome is an autosomal dominant condition that causes multiple benign tumors and cysts in various parts of the body, including the brain, spinal cord, eyes, adrenals, kidneys, and pancreas. It increases the risk of renal and pancreatic cancer but has no association with colorectal cancer.

Prior to initiating tamoxifen treatment, women should be informed about the elevated risk of VTE, which is one of the most significant side effects of the medication. Additionally, tamoxifen has been linked to an increased risk of endometrial cancer.

Venous Thromboembolism: Common Risk Factors

Venous thromboembolism (VTE) is a condition where blood clots form in the veins, which can lead to serious complications such as pulmonary embolism (PE). While there are many factors that can increase the risk of VTE, some are more common than others. These include malignancy, pregnancy, and the period following an operation. Other general risk factors include advancing age, obesity, family history of VTE, immobility, hospitalization, anaesthesia, and the use of central venous catheters. Underlying conditions such as heart failure, thrombophilia, and antiphospholipid syndrome can also increase the risk of VTE. Additionally, certain medications like the combined oral contraceptive pill, hormone replacement therapy, raloxifene, tamoxifen, and antipsychotics have been shown to be risk factors.

It is important to note that while these factors can increase the risk of VTE, around 40% of patients diagnosed with a PE have no major risk factors.

Breast cancer management varies depending on the stage of the cancer, type of tumor, and patient’s medical history. Treatment options may include surgery, radiotherapy, hormone therapy, biological therapy, and chemotherapy. Surgery is typically the first option for most patients, except for elderly patients with metastatic disease who may benefit more from hormonal therapy. Prior to surgery, an axillary ultrasound is recommended for patients without palpable axillary lymphadenopathy, while those with clinically palpable lymphadenopathy require axillary node clearance. The type of surgery offered depends on various factors, such as tumor size, location, and type. Breast reconstruction is also an option for patients who have undergone a mastectomy.

Radiotherapy is recommended after a wide-local excision to reduce the risk of recurrence, while mastectomy patients may receive radiotherapy for T3-T4 tumors or those with four or more positive axillary nodes. Hormonal therapy is offered if tumors are positive for hormone receptors, with tamoxifen being used in pre- and peri-menopausal women and aromatase inhibitors like anastrozole in post-menopausal women. Tamoxifen may increase the risk of endometrial cancer, venous thromboembolism, and menopausal symptoms. Biological therapy, such as trastuzumab, is used for HER2-positive tumors but cannot be used in patients with a history of heart disorders. Chemotherapy may be used before or after surgery, depending on the stage of the tumor and the presence of axillary node disease. FEC-D is commonly used in the latter case.

A young patient has a small fibroadenoma <3 cm, which is highly suggestive on imaging. There is no increase in the risk of breast cancer, so a core-needle biopsy is not necessary. Watchful waiting is appropriate, and cryoablation may be used for larger fibroadenomas. Fine-needle aspiration is only necessary for larger lumps or in older patients. Understanding Breast Fibroadenoma Breast fibroadenoma is a type of breast mass that develops from a whole lobule. It is characterized by a mobile, firm, and smooth lump in the breast, which is often referred to as a breast mouse. Fibroadenoma accounts for about 12% of all breast masses and is more common in women under the age of 30. Fortunately, fibroadenomas are usually benign and do not increase the risk of developing breast cancer. In fact, over a two-year period, up to 30% of fibroadenomas may even get smaller on their own. However, if the lump is larger than 3 cm, surgical excision is typically recommended. In summary, breast fibroadenoma is a common type of breast mass that is usually benign and does not increase the risk of breast cancer. While it may cause concern for some women, it is important to remember that most fibroadenomas do not require treatment and may even resolve on their own.

Tumour Markers for Common Cancers

Tumour markers are substances produced by cancer cells that can be detected in the blood. They are used to help diagnose and monitor the progression of cancer. Here are the most common tumour markers associated with some of the most prevalent cancers:

Hepatocellular carcinoma: Alpha-fetoprotein (AFP) is the most likely tumour marker associated with this type of liver cancer, which often develops in people with chronic liver diseases.

Breast cancer: Cancer antigen 15-3 (CA 15-3) is the most likely tumour marker associated with breast cancer, which affects both men and women.

Colorectal cancer: Carcinoembryonic antigen (CEA) is the most likely tumour marker associated with colorectal cancer, which can develop from polyps in the colon or rectum.

Pancreatic cancer: CA 19-9 is the most likely tumour marker associated with pancreatic cancer, which is often difficult to detect in its early stages.

Prostate cancer: Prostate-specific antigen (PSA) is the most likely tumour marker associated with prostate cancer, which is the most common cancer in men.

When a patient with sickle cell disease experiences dyspnoea, chest pain, cough, hypoxia, and new pulmonary infiltrates on chest x-ray, it is likely that they are suffering from acute chest syndrome. This is a complication specific to sickle cell anaemia, and is characterized by the presence of these symptoms along with the aforementioned pulmonary infiltrates.

Sickle cell anaemia is a condition that involves periods of good health with intermittent crises. There are several types of crises that can occur, including thrombotic or painful crises, sequestration, acute chest syndrome, aplastic, and haemolytic. Thrombotic crises, also known as painful crises or vaso-occlusive crises, are triggered by factors such as infection, dehydration, and deoxygenation. These crises are diagnosed clinically and can result in infarcts in various organs, including the bones, lungs, spleen, and brain.

Sequestration crises occur when sickling occurs within organs such as the spleen or lungs, leading to pooling of blood and worsening of anaemia. This type of crisis is associated with an increased reticulocyte count. Acute chest syndrome is caused by vaso-occlusion within the pulmonary microvasculature, resulting in infarction in the lung parenchyma. Symptoms include dyspnoea, chest pain, pulmonary infiltrates on chest x-ray, and low pO2. Management involves pain relief, respiratory support, antibiotics, and transfusion.

Aplastic crises are caused by infection with parvovirus and result in a sudden fall in haemoglobin. Bone marrow suppression leads to a reduced reticulocyte count. Haemolytic crises are rare and involve a fall in haemoglobin due to an increased rate of haemolysis. It is important to recognise and manage these crises promptly, as they can lead to serious complications and even death.

Vegan Nutrition: Understanding the Availability of Vitamins

As a vegan, it is important to understand the availability of vitamins in your diet. One vitamin that vegans are at risk of deficiency in is vitamin B12, which is primarily found in animal products such as meat, fish, eggs, and milk. However, there are vegan-friendly sources of vitamin B12 such as fortified cereals and plant-based milks.

Contrary to popular belief, vitamin B6, vitamin A, vitamin B1, and vitamin C are all readily available in vegan-friendly foods. Vitamin B6 can be found in bread, whole grains, vegetables, peanuts, and potatoes. Vitamin A can be found in yellow, red, and green vegetables as well as yellow fruits. Vitamin B1 can be found in peas, fruit, whole grain bread, and fortified cereals. Vitamin C is predominantly found in fruits and vegetables such as oranges, peppers, strawberries, broccoli, potatoes, and Brussels sprouts.

By understanding the availability of vitamins in vegan-friendly foods, vegans can ensure they are meeting their nutritional needs and maintaining a healthy diet.

Von Willebrand’s disease is a common genetic bleeding disorder that is inherited in an autosomal dominant manner. It behaves like a platelet disorder because von Willebrand Factor (vWF) is necessary for platelet adhesion to the damaged endothelium. As a result, patients experience mucocutaneous bleeding after minor injuries, such as nosebleeds and bruising. Bleeding time is prolonged because they cannot adhere to form the platelet plug, but the platelet count itself is normal. APTT is also prolonged because vWF acts as a carrier molecule for factor VIII, which is measured by APTT. This is also observed in haemophilia A, but to a greater extent.

Understanding Von Willebrand’s Disease

Von Willebrand’s disease is a common inherited bleeding disorder that is usually passed down in an autosomal dominant manner. It behaves like a platelet disorder, with symptoms such as nosebleeds and heavy menstrual bleeding being common, while joint and muscle bleeding are rare. The disease is caused by a deficiency or abnormality in von Willebrand factor, a large glycoprotein that promotes platelet adhesion to damaged endothelium and acts as a carrier molecule for factor VIII.

There are three types of Von Willebrand’s disease. Type 1 is the most common and is characterized by a partial reduction in von Willebrand factor. Type 2 is further divided into four subtypes, each with a different abnormality in the von Willebrand factor. Type 3 is the most severe form and is caused by a total lack of von Willebrand factor, inherited in an autosomal recessive manner.

Diagnosis of Von Willebrand’s disease involves tests such as a prolonged bleeding time, APTT, factor VIII levels, and platelet aggregation with ristocetin. Management options include tranexamic acid for mild bleeding, desmopressin to raise levels of von Willebrand factor, and factor VIII concentrate. While there is no clear correlation between symptomatic presentation and type of Von Willebrand’s disease, common themes among patients include excessive mucocutaneous bleeding, bruising in the absence of trauma, and menorrhagia in females.

Treatment Options for Acute Leukaemia

Acute leukaemia, specifically acute myeloid leukaemia (AML), is characterized by an increase in undifferentiated blast cells in the bone marrow and blood, leading to marrow failure. The traditional treatment approach for AML involves three components: induction, consolidation, and maintenance chemotherapy. Combination chemotherapy is used to eradicate blast cells, with maintenance chemotherapy given to eliminate any remaining disease.

Iron transfusions may be necessary to treat anaemia or platelet deficiency, but they are not a direct treatment for acute leukaemia. Patients with leukaemia are at risk of graft-versus-host disease, so they are given irradiated blood components.

Intravenous immunoglobulins are not a treatment for acute leukaemia but may be used to prevent infection in patients with hypogammaglobulinaemia resulting from cancer treatment.

Radiotherapy is not a first-line treatment for acute leukaemia, but it may be used to treat disease that has spread to the brain or spinal cord. Total body radiotherapy can also be used before a stem-cell transplant to reduce the risk of transplant rejection.

Stem-cell transplants can be allogeneic (from a matched or partially matched donor) or autologous (from the patient’s own stem cells) and are used after remission induction with chemotherapy. The goal is to restore the body’s ability to produce normal blood cells and can be curative, but it is not a first-line treatment.

Understanding Treatment Options for Acute Leukaemia

Palliative Care Prescribing for Agitation and Confusion

When dealing with agitation and confusion in palliative care patients, it is important to identify and treat any underlying causes such as hypercalcaemia, infection, urinary retention, or medication. If these specific treatments fail, medication can be used to manage symptoms. Haloperidol is the first choice for treating agitation and confusion, with chlorpromazine and levomepromazine as alternative options. In the terminal phase of the illness, midazolam is the preferred medication for managing agitation or restlessness. Proper management of these symptoms can greatly improve the quality of life for palliative care patients.

Clinical Signs and Symptoms of Bronchial Neoplasm and SVCO

Bronchial neoplasm is highly likely in a patient presenting with venous dilatation over the anterior chest wall. The presence of facial swelling should alert healthcare professionals to the possibility of superior vena cava obstruction (SVCO), which can cause dilated subcutaneous veins, tissue edema, and shortness of breath. An SVCO is an oncological emergency that requires prompt treatment with steroids and diuretics. Lung carcinoma is the most common cause of SVCO, but it can also be caused by lymphomas and other types of cancer.

Other clinical signs and symptoms that may indicate lung cancer include expiratory wheeze, supraclavicular or cervical lymphadenopathy, finger clubbing, and cranial nerve palsy. However, these signs and symptoms are non-specific and may also be present in other chronic diseases. It is important to consider the patient’s overall clinical picture and perform appropriate diagnostic tests to confirm the diagnosis and determine the underlying cause of the symptoms.

MGUS is a possible differential diagnosis for elevated paraproteins in the blood.

Thrombocytopenia is a characteristic feature of haemolytic uraemic syndrome.

The presence of paraproteins in the blood is an abnormal finding and not a normal variant.

While a viral infection may cause neutropenia, it would not typically result in the presence of paraproteins in the blood.

Paraproteinaemia is a medical condition characterized by the presence of abnormal proteins in the blood. There are various causes of paraproteinaemia, including myeloma, monoclonal gammopathy of uncertain significance (MGUS), benign monoclonal gammopathy, Waldenstrom’s macroglobulinaemia, amyloidosis, CLL, lymphoma, heavy chain disease, and POEMS. Benign monoclonal gammopathy can also cause paraproteinaemia, as well as non-lymphoid malignancy (such as colon or breast cancer), infections (such as CMV or hepatitis), and autoimmune disorders (such as RA or SLE).

Paraproteinaemia is a medical condition that is characterized by the presence of abnormal proteins in the blood. This condition can be caused by various factors, including myeloma, MGUS, benign monoclonal gammopathy, Waldenstrom’s macroglobulinaemia, amyloidosis, CLL, lymphoma, heavy chain disease, and POEMS. Additionally, benign monoclonal gammopathy, non-lymphoid malignancy (such as colon or breast cancer), infections (such as CMV or hepatitis), and autoimmune disorders (such as RA or SLE) can also cause paraproteinaemia. It is important to identify the underlying cause of paraproteinaemia in order to determine the appropriate treatment plan.

Anastrozole, an aromatase inhibitor, is a recommended adjuvant therapy for patients with oestrogen positive cancer (ER+). However, it may lead to osteoporosis as an adverse effect. Therefore, NICE recommends performing a DEXA scan before initiating therapy. A clotting screen is not necessary before starting anastrozole, as it does not cause coagulopathies. ECGs are not required either, as cardiac changes and arrhythmias are not associated with this medication. Unlike certain medications like statins, anastrozole is not known to commonly affect lipid profiles, so it does not need to be monitored. Liver function tests are also not routinely assessed before starting anastrozole, as it is not known to affect liver function. However, it would have been appropriate to send a clotting screen before the patient’s lumpectomy.

Anti-oestrogen drugs are used in the management of oestrogen receptor-positive breast cancer. Selective oEstrogen Receptor Modulators (SERM) such as Tamoxifen act as an oestrogen receptor antagonist and partial agonist. However, Tamoxifen can cause adverse effects such as menstrual disturbance, hot flushes, venous thromboembolism, and endometrial cancer. On the other hand, aromatase inhibitors like Anastrozole and Letrozole reduce peripheral oestrogen synthesis, which is important in postmenopausal women. Anastrozole is used for ER +ve breast cancer in this group. However, aromatase inhibitors can cause adverse effects such as osteoporosis, hot flushes, arthralgia, myalgia, and insomnia. NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors for breast cancer.

Peripheral neuropathy is a known side effect of Vincristine. Additionally, bladder atony may cause urinary hesitancy.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin, degrade preformed DNA and can lead to lung fibrosis. Anthracyclines, such as doxorubicin, stabilize the DNA-topoisomerase II complex and inhibit DNA and RNA synthesis, but can also cause cardiomyopathy. Antimetabolites, like methotrexate, inhibit dihydrofolate reductase and thymidylate synthesis, leading to myelosuppression, mucositis, liver fibrosis, and lung fibrosis. Fluorouracil (5-FU) is a pyrimidine analogue that induces cell cycle arrest and apoptosis by blocking thymidylate synthase, but can also cause myelosuppression, mucositis, and dermatitis. Cytarabine is a pyrimidine antagonist that interferes with DNA synthesis specifically at the S-phase of the cell cycle and inhibits DNA polymerase, but can also cause myelosuppression and ataxia. Drugs that act on microtubules, like vincristine and vinblastine, inhibit the formation of microtubules and can cause peripheral neuropathy, paralytic ileus, and myelosuppression. Docetaxel prevents microtubule depolymerisation and disassembly, decreasing free tubulin, but can also cause neutropaenia. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I which prevents relaxation of supercoiled DNA, but can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin, cause cross-linking in DNA and can lead to ototoxicity, peripheral neuropathy, and hypomagnesaemia. Hydroxyurea (hydroxycarbamide) inhibits ribonucleotide reductase, decreasing DNA synthesis, but can also cause myelosuppression.

Understanding Haemochromatosis: Symptoms, Causes, and Complications

Haemochromatosis is a genetic disorder that affects iron absorption and metabolism, leading to the accumulation of iron in the body. It is caused by mutations in the HFE gene on both copies of chromosome 6. This disorder is more common in people of European descent, with a prevalence of 1 in 200.

In the early stages of haemochromatosis, symptoms are often non-specific, such as fatigue and joint pain. As the disease progresses, patients may develop bronze skin pigmentation, diabetes mellitus, liver disease, cardiac failure, hypogonadism, and arthritis.

Treatment for haemochromatosis involves regular phlebotomy to remove excess iron from the body. Reversible complications of haemochromatosis include cardiomyopathy, skin pigmentation, liver cirrhosis, diabetes mellitus, hypogonadotrophic hypogonadism, and arthropathy. However, irreversible complications include cirrhosis, which can lead to liver failure and other serious health problems.

In conclusion, haemochromatosis is a genetic disorder that affects iron metabolism and can lead to serious health complications if left untreated. Early diagnosis and treatment can help prevent irreversible damage and improve quality of life for affected individuals.

Small-cell carcinoma of the lung (SCLC) is a type of lung cancer that is often associated with a condition called syndrome of inappropriate antidiuretic hormone syndrome (SIADH). SIADH is caused by the abnormal release of anti-diuretic hormone (ADH), which leads to impaired water excretion and hyponatremia. This can result in symptoms such as nausea, weakness, confusion, and seizures. While SCLC is the most common cause of SIADH, it can also be caused by other types of cancer, certain drugs, intracranial lesions, and infections. Squamous-cell carcinoma (SCC) of the lung, on the other hand, does not typically result in SIADH as it does not originate from neuroendocrine cells. Pancreatic cancer can also cause SIADH, but it is less common than in SCLC. Prostate cancer, which is the second most common cancer globally, does not usually present with hormonal effects but rather with lower urinary tract symptoms. Bronchial carcinoid tumors, which are neuroendocrine tumors of the lung, can cause hormonal effects such as weight gain, high blood pressure, and hirsutism, but these symptoms are not indicated in the scenario given.

Platelet transfusions have the highest risk of bacterial contamination due to their short shelf life and refrigeration. This patient requires both red blood cells and platelets, but caution should be taken with platelet transfusions due to the risk of contamination. Cryoprecipitate and plasma have lower contamination risks and can be stored for longer periods. Packed red cells can also be used and have a longer shelf life.

Platelet Transfusion Guidelines for Active Bleeding and Pre-Invasive Procedures

Platelet transfusions are recommended for patients with thrombocytopenia and clinically significant bleeding, such as haematemesis, melaena, or prolonged epistaxis, with a platelet count of less than 30 x 10 9. For severe bleeding or bleeding at critical sites, such as the CNS, platelet thresholds for transfusion are higher, with a maximum of less than 100 x 10 9. However, it should be noted that platelet transfusions have a higher risk of bacterial contamination compared to other types of blood products.

For pre-invasive procedures, platelet transfusions are recommended to maintain platelet levels of greater than 50 x 10 9/L for most patients, 50-75 x 10 9/L for those at high risk of bleeding, and greater than 100 x 10 9/L for surgeries at critical sites. However, if there is no active bleeding or planned invasive procedure, a threshold of 10 x 10 9/L is recommended, unless platelet transfusion is contraindicated or there are alternative treatments available for the patient’s condition.

It is important to note that platelet transfusions should not be performed for chronic bone marrow failure, autoimmune thrombocytopenia, heparin-induced thrombocytopenia, or thrombotic thrombocytopenic purpura. These guidelines aim to provide appropriate and safe platelet transfusion practices for patients with thrombocytopenia.

The most likely diagnosis for the patient’s deranged vital signs after a major operation and suspected sepsis is disseminated intravascular coagulation (DIC). This is characterized by low platelets, increased clotting time, and raised fibrin degradation products (FDPs). DIC is often caused by the release of tissue factor (TF) in response to cytokines, tumor necrosis factor, and endotoxin. Anastomotic leak, heparin-induced thrombocytopenia, warfarin use, and aspirin use are unlikely causes based on the patient’s history and blood results.

Understanding Disseminated Intravascular Coagulation (DIC) Diagnosis

Under normal conditions, coagulation and fibrinolysis work together to maintain homeostasis. However, in DIC, these processes become dysregulated, leading to widespread clotting and bleeding. One key factor in the development of DIC is the release of tissue factor (TF), a glycoprotein found on the surface of various cell types. Normally, TF is not in contact with the general circulation, but it is exposed after vascular damage or in response to certain cytokines. Once activated, TF triggers the extrinsic pathway of coagulation, which then triggers the intrinsic pathway. DIC can be caused by various factors, including sepsis, trauma, obstetric complications, and malignancy.

To diagnose DIC, a typical blood picture will show decreased platelets and fibrinogen, increased fibrinogen degradation products, and the presence of schistocytes due to microangiopathic hemolytic anemia. Additionally, both the prothrombin time and activated partial thromboplastin time are prolonged, while bleeding time and platelet count are often low. Understanding the diagnosis of DIC is crucial for prompt and effective treatment.

Distinguishing Multiple Myeloma from Other Bone Diseases

Multiple Myeloma: A Malignant Disease of Plasma Cells

Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is more common in black Africans and rare in Asians, with a median age of onset over 60. Patients may not show any symptoms and are often diagnosed through routine blood tests. However, they are more susceptible to infections and may have low white blood cell counts. Elevated levels of ESR and CRP are almost always present. Diagnosis is confirmed when two out of three of the following are present: paraproteinaemia or Bence Jones protein, radiological evidence of lytic bone lesions, and an increase in bone marrow plasma cells. Patients may experience bone pain, lethargy, thirst, and anaemia, which are all signs of multiple myeloma.

Calcium Pyrophosphate Arthropathy: Shedding of Crystals into Joints

Calcium pyrophosphate arthropathy, also known as pseudogout, is caused by the shedding of calcium pyrophosphate crystals into the joint. It typically presents as an acute-onset monoarticular arthritis, usually in the knee or wrist. The joint will be hot, red, tender, and swollen. Rhomboid-shaped crystals that are weakly positively birefringent under polarised light will be visible in synovial fluid.

Osteoporosis: Fragility Fractures

Osteoporosis is characterised by fragility fractures, such as vertebral crush fractures, Colles fractures, and fractures of the proximal femur. It is uncommon in men at this age, unless associated with hypogonadism. Anaemia and elevated ESR are not seen in osteoporosis.

Osteoarthritis: Joint Pain and Stiffness

Osteoarthritis presents with joint pain, stiffness, and reduced function. The weight-bearing joints, such as the hip and knee, and the small joints of the hand are commonly affected. Patients do not experience symptoms such as thirst and lethargy, which are due to hypercalcaemia. Blood biochemistry is normal in osteoarthritis.

Paget’s Disease of Bone: Bone Remodelling

Paget’s disease of the bone is rare in individuals under 40 years old. It is characterised by bone pain, deformity, fragility fractures, and complications from nerve compression

Differential Diagnosis for Obstructive Jaundice in a Patient with Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that increases the risk of developing hepatobiliary cancers. When a patient with UC presents with obstructive jaundice, the most likely diagnosis is cholangiocarcinoma, as evidenced by a raised bilirubin with normal transaminases but raised ALP and GGT.

Other potential causes of obstructive jaundice include gallstones, which typically present with right upper quadrant pain and fever, and gallbladder empyema if the patient is acutely unwell. Haemochromatosis, an inherited condition that causes liver damage due to excessive iron absorption, would present with raised transaminases rather than obstructive jaundice.

Hepatocellular carcinoma (HCC) is another potential diagnosis in a patient with UC, but it is characterized by raised transaminases and ALP. Non-alcoholic fatty liver disease (NAFLD), which results from a build-up of fat in the liver, is more common in individuals who are obese, have type II diabetes, hyperlipidaemia, or metabolic syndrome, and would present with raised transaminases rather than ALP and GGT.

In summary, when a patient with UC presents with obstructive jaundice, cholangiocarcinoma should be the primary consideration, but other potential causes should also be evaluated.

Causes of Different Types of Anaemia

Anaemia is a condition characterized by a decrease in the number of red blood cells or a decrease in the amount of haemoglobin in the blood. There are different types of anaemia, and each has its own causes. Here are some of the causes of different types of anaemia:

Impaired Vitamin B12 Absorption: Vitamin B12 deficiency is a potential consequence of ileal resection and Crohn’s disease. Vitamin B12 injections may be required. Vitamin B12 deficiency causes a macrocytic anaemia.

Impaired Iron Absorption: Iron deficiency causes a microcytic anaemia. Iron deficiency anaemia is multifactorial, with gastrointestinal (GI), malabsorption and gynaecological causes being the most common causes. Ileal resection is not associated with impaired iron absorption, but gastrectomy can be.

Chronic Bleeding after Surgery: Iron deficiency due to chronic blood loss causes a microcytic anaemia. Acute blood loss would cause a normocytic anaemia.

Haemolysis: Haemolysis is the abnormal destruction of red blood cells. It causes a normocytic anaemia.

Bacterial Infection: A bacterial infection is not a common cause of anaemia.

For cancer patients with VTE, the recommended treatment is a DOAC for a period of 6 months. Among the DOACs, apixaban is the most suitable option as it has been found to have a lower risk of bleeding complications compared to LMWH and VKA. Moreover, patients taking apixaban can benefit from oral treatment and avoid frequent monitoring required with other anticoagulation treatments. Studies have also shown that apixaban is the most cost-effective option as it results in fewer bleeds.

NICE updated their guidelines on the investigation and management of venous thromboembolism (VTE) in 2020. The use of direct oral anticoagulants (DOACs) is recommended as first-line treatment for most people with VTE, including as interim anticoagulants before a definite diagnosis is made. Routine cancer screening is no longer recommended following a VTE diagnosis. The cornerstone of VTE management is anticoagulant therapy, with DOACs being the preferred choice. All patients should have anticoagulation for at least 3 months, with the length of anticoagulation being determined by whether the VTE was provoked or unprovoked.

The typical blood picture for DIC includes a decrease in platelets and fibrinogen levels, as well as an increase in PT and APTT, and fibrinogen degradation products. DIC can be triggered by trauma, malignancies, and other factors. The patient’s symptoms, such as oliguria, hypotension, and tachycardia, suggest circulatory collapse due to DIC. Bleeding at multiple sites, including haematuria, petechial bruising, and bleeding from a peripheral cannula, is also common in DIC. The release of procoagulants in DIC leads to widespread clotting activation, which consumes platelets and clotting factors, resulting in a low platelet count and prolonged bleeding times. Fibrinolysis is also activated, leading to low fibrinogen levels and high D-dimer levels. Additionally, haemoglobin levels may be low due to bleeding and lysis caused by fibrin strands in small blood vessels.

Understanding Disseminated Intravascular Coagulation (DIC) Diagnosis

Under normal conditions, coagulation and fibrinolysis work together to maintain homeostasis. However, in DIC, these processes become dysregulated, leading to widespread clotting and bleeding. One key factor in the development of DIC is the release of tissue factor (TF), a glycoprotein found on the surface of various cell types. Normally, TF is not in contact with the general circulation, but it is exposed after vascular damage or in response to certain cytokines. Once activated, TF triggers the extrinsic pathway of coagulation, which then triggers the intrinsic pathway. DIC can be caused by various factors, including sepsis, trauma, obstetric complications, and malignancy.

To diagnose DIC, a typical blood picture will show decreased platelets and fibrinogen, increased fibrinogen degradation products, and the presence of schistocytes due to microangiopathic hemolytic anemia. Additionally, both the prothrombin time and activated partial thromboplastin time are prolonged, while bleeding time and platelet count are often low. Understanding the diagnosis of DIC is crucial for prompt and effective treatment.

To effectively manage sickle cell crisis, it is essential to administer analgesia, oxygen, and IV fluids. In addition, antibiotics may be necessary if an infection is suspected, and transfusion may be required if the patient’s Hb levels are low.

It is not advisable to simply monitor patients without providing any treatment, as this would result in significant pain and discomfort.

The most effective approach involves a combination of oxygen, fluids, and analgesia. Pain management is crucial, as the blockage of blood vessels by sickle-shaped red blood cells prevents the delivery of oxygen and blood to the tissues, resulting in pain. Oxygen supplementation is necessary to alleviate this pain, and IV fluids can help to slow or halt the sickling process. None of these components alone would be sufficient in managing pain, but together they form a comprehensive approach to pain management.

Managing Sickle-Cell Crises

Sickle-cell crises can be managed through various interventions. General management includes providing analgesia, rehydration, and oxygen. Antibiotics may also be considered if there is evidence of infection. Blood transfusion may be necessary for severe or symptomatic anemia, pregnancy, or pre-operative cases. However, it is important not to rapidly reduce the percentage of Hb S containing cells.

In cases of acute vaso-occlusive crisis, such as stroke, acute chest syndrome, multiorgan failure, or splenic sequestration crisis, exchange transfusion may be necessary. This involves rapidly reducing the percentage of Hb S containing cells. It is important to note that the management of sickle-cell crises should be tailored to the individual patient’s needs and medical history. Proper management can help alleviate symptoms and prevent complications.

For provoked cases of venous thromboembolism, such as those following recent surgery, warfarin treatment is typically recommended for a duration of three months. However, for unprovoked cases, where the cause is unknown, a longer duration of six months is typically recommended.

NICE updated their guidelines on the investigation and management of venous thromboembolism (VTE) in 2020. The use of direct oral anticoagulants (DOACs) is recommended as first-line treatment for most people with VTE, including as interim anticoagulants before a definite diagnosis is made. Routine cancer screening is no longer recommended following a VTE diagnosis. The cornerstone of VTE management is anticoagulant therapy, with DOACs being the preferred choice. All patients should have anticoagulation for at least 3 months, with the length of anticoagulation being determined by whether the VTE was provoked or unprovoked.

Understanding the Causes of Normocytic Anaemia in a Patient with Rheumatoid Arthritis

The patient in question has been diagnosed with normocytic anaemia, which is characterized by normal MCV and MCH results. There are several potential causes of this type of anaemia, including renal failure, anaemia of chronic disease, and mixed iron and vitamin B12 or folate deficiency. However, given that the patient has rheumatoid arthritis (RA) and normal renal function, the most likely cause of her anaemia is a chronic disease. This is thought to be the result of chronic inflammation associated with diseases such as RA.

One potential complication of RA is Felty syndrome, which is characterized by a triad of conditions: RA, splenomegaly, and neutropenia. However, this patient has a normal WCC and neutrophil count, which rules out this diagnosis.

Vitamin B12 deficiency can also cause anaemia, but it typically results in macrocytic anaemia characterized by a raised MCV. In contrast, this patient has a normal MCV. Vitamin B12 deficiency is typically treated with oral supplements, unless intrinsic antibodies are present, in which case intramuscular B12 is needed.

Folate deficiency can also drive macrocytic anaemia, but this patient demonstrates normocytic anaemia. Methotrexate, which is commonly used to treat RA, is a folate antagonist, which is why the patient is also taking folic acid supplements to reduce the risk of developing folate deficiency.

Iron deficiency is another potential cause of anaemia, but it typically results in microcytic hypochromic anaemia characterized by low MCV and MCH. In contrast, this patient has normal MCV and MCH results. A combination of iron and vitamin B12 or folate deficiencies may result in normocytic anaemia, as can acute blood loss.

Treatment Options for Acute Leukaemia: Chemotherapy, Stem-Cell Transplant, Blood Transfusion, Intravenous Immunoglobulins, and Radiotherapy

Acute leukaemias, such as acute lymphoblastic leukaemia (ALL), are characterized by an increase in primitive undifferentiated blast cells in the bone marrow and blood, leading to marrow failure. The traditional treatment for ALL involves four components: induction, consolidation, maintenance, and central nervous system (CNS) prophylaxis. The first-line therapy for ALL is combination chemotherapy, which aims to eradicate the blast cells. Once remission is induced, maintenance chemotherapy is given to eliminate the disease that cannot be detected under the microscope.

Stem-cell transplants can be used to treat ALL once remission is induced using chemotherapy. This treatment can be allogeneic (the patient receives stem cells from a matched or partially mismatched related or unrelated donor) or autologous (the patient receives their own stem cells). The goal of a stem-cell transplant is to restore the body’s ability to produce normal blood cells. While it can be a curative treatment for patients with this disease, it is not used as a first-line treatment.

Blood transfusions are not a treatment for acute leukaemia, but they may be necessary to treat anaemia or platelet deficiency. Patients with leukaemia are at risk of graft-versus-host disease, so they are typically given irradiated blood components. Intravenous immunoglobulins are not used to treat acute leukaemia but may be used prophylactically against infection in patients with hypogammaglobulinaemia due to cancer treatment.

Radiotherapy is not a first-line treatment for acute leukaemia, but it may be used to treat the brain or spinal cord if the disease has spread there. Total body radiotherapy may also be used before a stem-cell transplant to suppress the immune system and reduce the risk of transplant rejection.

Lower gastrointestinal tract investigation should be conducted on any patient in this age group who has an unexplained microcytic anaemia to rule out the possibility of colorectal cancer.

Referral Guidelines for Colorectal Cancer

Colorectal cancer is a serious condition that requires prompt diagnosis and treatment. In 2015, the National Institute for Health and Care Excellence (NICE) updated their referral guidelines for patients suspected of having colorectal cancer. According to these guidelines, patients who are 40 years or older with unexplained weight loss and abdominal pain, 50 years or older with unexplained rectal bleeding, or 60 years or older with iron deficiency anemia or change in bowel habit should be referred urgently to colorectal services for investigation. Additionally, patients who test positive for occult blood in their feces should also be referred urgently.

An urgent referral should also be considered for patients who have a rectal or abdominal mass, unexplained anal mass or anal ulceration, or are under 50 years old with rectal bleeding and any of the following unexplained symptoms/findings: abdominal pain, change in bowel habit, weight loss, or iron deficiency anemia.

The NHS offers a national screening program for colorectal cancer, which involves sending eligible patients aged 60 to 74 years in England and 50 to 74 years in Scotland FIT tests through the post. FIT is a type of fecal occult blood test that uses antibodies to detect and quantify the amount of human blood in a single stool sample. Patients with abnormal results are offered a colonoscopy.

The FIT test is also recommended for patients with new symptoms who do not meet the 2-week criteria listed above. For example, patients who are 50 years or older with unexplained abdominal pain or weight loss, under 60 years old with changes in their bowel habit or iron deficiency anemia, or 60 years or older who have anemia even in the absence of iron deficiency. Early detection and treatment of colorectal cancer can significantly improve patient outcomes, making it important to follow these referral guidelines.